-

PerkinElmer Launches ChemDraw® V21 Software, Empowering Researchers to Rapidly Create Chemically Intelligent Microsoft PowerPoint Reports

Ability to import 3D molecular models with one click accelerates information sharing, collaboration and decision making

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced V21 of its ChemDraw® software featuring the ability to import, animate and share 3D chemical structures natively in the Microsoft® PowerPoint® application with one click. The key enhancement, to a tool used by millions of scientists around the world, helps chemists create more intelligent research reports quickly and easily -- improving information sharing and collaboration and supporting real-time decision making.

Using the new ChemDraw V21 software, chemists simply paste a live 3D rendering of their molecule, with its atom and bond color highlights fully retained, natively into the Microsoft PowerPoint application where they can view, rotate and share the image. Researchers can also save molecules as 3D printable objects. No other chemical drawing application in the industry today provides these intuitive capabilities which eliminate the need to use specialized software with steep learning curves.

Part of the PerkinElmer® ChemOffice®+ Cloud platform, the software also continues to allow users to quickly perform chemical structure searches across disparate Microsoft documents and easily create reports of their chemistry experiments in PerkinElmer’s cloud-native Signals Notebook™ electronic lab notebook (ELN).

“ChemDraw software and the ChemOffice+ Cloud platform are all about simplifying, facilitating, and accelerating chemistry communication to transform drawings into shareable knowledge,” said Kevin Willoe, VP and GM of PerkinElmer Informatics. “With this latest ChemDraw software release, chemists working on new drugs or materials can go from a 2D to 3D world more efficiently and help drive fluid collaboration and data-rich, timely decision making.”

ChemDraw software is part of PerkinElmer’s extensive informatics portfolio which is used by more than 2 million scientists around the globe today. Pharmaceutical, agrochemical, advanced materials, and food industries rely on PerkinElmer’s cloud-based, electronic notebook and laboratory informatics solutions to capture, store and analyze research data, collaborate, and support data-driven R&D and clinical decisions.

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5.0 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

Contacts

Media
Jennifer McNeil
Jennifer.Mcneil@perkinelmer.com
+1 508-380-2902

PerkinElmer, Inc.

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Summary
ChemDraw® V21 software supports import, animation and sharing of 3D chemical structures natively in Microsoft® PowerPoint® with one click.
Release Versions

Contacts

Media
Jennifer McNeil
Jennifer.Mcneil@perkinelmer.com
+1 508-380-2902

More News From PerkinElmer, Inc.

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acce...

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: UBS Global Healthcare Conference 2025 Monday, November 10, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Jefferies 2025 London Healthcare Conference Tuesday, November 18, 2025 2:00 p.m. GMT – Max Krakowiak Citi's 2025 Global Healthcare Conference Tuesday, December 2, 2025 9:00 a.m. ET – Prahlad Singh, president and chief execu...

Revvity Announces Financial Results for the Third Quarter of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025. The Company reported GAAP earnings per share of $0.40, as compared to $0.77 in the same period a year ago. Revenue for the quarter was $699 million, as compared to $684 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $82 million, as compared to $98 million for the same period a year ago. GAAP ope...
Back to Newsroom